Loperamide vs Hydrocodone Bitartrate and Homatropine Methylbromide — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Opioid Agonist

Loperamide

First FDA approval: 1991-09-18

Opioid Agonist

Hydrocodone Bitartrate and Homatropine Methylbromide

Brand: Hycodan

First FDA approval: 2002-09-30

Lowest NADACAcquisition cost floor across all NDCs

$0.053Per unit

$0.098Per unit

Average NADACAcross all dosage forms and strengths

$0.053Up to $0.053

$0.675Up to $0.964

Generic manufacturersActive ANDA holders — FDA Orange Book

88 total ANDAs filed

66 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$24.5MFull year

—Full year

Part D claims (CY24)Total fills, all strengths

1.4M709K beneficiaries

—— beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$18Per claim, all NDCs

—Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

—Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

—None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

DiscontinuedSee drug profile

Generic availableFDA Orange Book

Yes8 manufacturers

Yes6 manufacturers